Government Briefs

Hitting The Magic Billion-Dollar Mark The recent AIDS report by the Institute of Medicine got a lot of play in the press for its criticism of federal efforts on behalf of drug abusers and AIDS sufferers facing discrimination. But the report also contains an important message for researchers. Entitled Confronting AIDS: Update 1988” because it follows up on IOM’s landmark 1986 report, the study calls on the NIH director to evaluate how well the government is spending its money in a s

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The recent AIDS report by the Institute of Medicine got a lot of play in the press for its criticism of federal efforts on behalf of drug abusers and AIDS sufferers facing discrimination. But the report also contains an important message for researchers. Entitled Confronting AIDS: Update 1988” because it follows up on IOM’s landmark 1986 report, the study calls on the NIH director to evaluate how well the government is spending its money in a search for a vaccine and eventual cure for the disease. The fact that research spending is expected to reach $1 billion by fiscal 1990, notes the report, requires “an assessment of the need for further increases, to ensure that other federal research programs are not penalized by a long-term disproportionate growth in the AIDS budget.” The panel, headed by Upjohn CEO Theodore Cooper, also suggests that NIH calculate and tell Congress how much more ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies